CN110964678A - Genetically engineered bacterium for synthesizing farnesene and construction method and application thereof - Google Patents

Genetically engineered bacterium for synthesizing farnesene and construction method and application thereof Download PDF

Info

Publication number
CN110964678A
CN110964678A CN201811144959.7A CN201811144959A CN110964678A CN 110964678 A CN110964678 A CN 110964678A CN 201811144959 A CN201811144959 A CN 201811144959A CN 110964678 A CN110964678 A CN 110964678A
Authority
CN
China
Prior art keywords
gene
farnesene
aafs
ispa
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201811144959.7A
Other languages
Chinese (zh)
Other versions
CN110964678B (en
Inventor
咸漠
门潇
张海波
许子燕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qingdao Institute of Bioenergy and Bioprocess Technology of CAS
Original Assignee
Qingdao Institute of Bioenergy and Bioprocess Technology of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qingdao Institute of Bioenergy and Bioprocess Technology of CAS filed Critical Qingdao Institute of Bioenergy and Bioprocess Technology of CAS
Priority to CN201811144959.7A priority Critical patent/CN110964678B/en
Publication of CN110964678A publication Critical patent/CN110964678A/en
Application granted granted Critical
Publication of CN110964678B publication Critical patent/CN110964678B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P5/00Preparation of hydrocarbons or halogenated hydrocarbons
    • C12P5/02Preparation of hydrocarbons or halogenated hydrocarbons acyclic
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0006Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1025Acyltransferases (2.3)
    • C12N9/1029Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88Lyases (4.)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90Isomerases (5.)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y101/00Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01088Hydroxymethylglutaryl-CoA reductase (1.1.1.88)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y203/00Acyltransferases (2.3)
    • C12Y203/01Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01016Acetyl-CoA C-acyltransferase (2.3.1.16)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01036Mevalonate kinase (2.7.1.36)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/07Diphosphoric monoester hydrolases (3.1.7)
    • C12Y301/07006Farnesyl diphosphatase (3.1.7.6)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y401/00Carbon-carbon lyases (4.1)
    • C12Y401/01Carboxy-lyases (4.1.1)
    • C12Y401/01033Diphosphomevalonate decarboxylase (4.1.1.33), i.e. mevalonate-pyrophosphate decarboxylase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y402/00Carbon-oxygen lyases (4.2)
    • C12Y402/03Carbon-oxygen lyases (4.2) acting on phosphates (4.2.3)
    • C12Y402/03047Beta-farnesene synthase (4.2.3.47)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y503/00Intramolecular oxidoreductases (5.3)
    • C12Y503/01Intramolecular oxidoreductases (5.3) interconverting aldoses and ketoses (5.3.1)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention provides a genetically engineered bacterium for synthesizing farnesene, which aims to solve the problems that a heterologous MVA (multi-domain vertical multi-domain) downstream path in a farnesene synthesizing process of escherichia coli is low in catalytic efficiency, intermediate metabolites such as IPP (isopropyl-propylene phosphate)/DMAPP (dimethyl propyl methacrylate) are toxic to a host and the farnesene yield is further improved.

Description

Genetically engineered bacterium for synthesizing farnesene and construction method and application thereof
Technical Field
The invention belongs to the technical field of microorganisms, and particularly relates to a genetically engineered bacterium for synthesizing farnesene, and a construction method and application thereof.
Background
Farnesene (farnesene), also called farnesene and sesquicitronellaene, is a chain sesquiterpene compound with molecular formula C15H24The farnesene has 6 different configurations such as cis/trans, - α, - β and the like, and is usually a mixture of a plurality of isomers.
The synthetic pathways for natural farnesene are mainly the mevalonate pathway (MVA) and the 2-methyl-D-erythritol-4-phosphate pathway (2-methyl-D-erythrorito-4-phosphate, MEP) present in plants and the terpenoid synthetic pathway downstream of both. The farnesene extracted from the plant has low yield, high cost and limitation of raw materials, and the components are complex, so that the product with single configuration and high purity cannot be obtained. Therefore, from the last 60 s, methods for synthesizing farnesene from nerolidol, farnesol, myrcene, geranyl bromide, and the like, respectively, have been developed. The chemical synthesis method improves the yield of farnesene, can obtain a product with single configuration and higher purity, but also has the problems of special instrument and equipment, complex operation flow, high energy consumption, easy pollution generation and the like.
In recent years, farnesene can be synthesized by using engineering microorganisms through metabolic engineering, but the problems of unbalanced metabolic flow of a heterologous pathway, toxicity of intermediate metabolites to host cells and the like still exist.
Disclosure of Invention
In order to solve the problems that the catalytic efficiency of a heterologous MVA downstream pathway is low, intermediate metabolites such as IPP/DMAPP have toxicity to a host and the yield of farnesene is further improved in the process of synthesizing farnesene by escherichia coli, the technical scheme adopted by the invention is as follows:
the invention improves the catalytic efficiency of the MVA downstream pathway and reduces the accumulation of toxic intermediates by increasing the copy number of key genes idi and ispA in a host. The plasmid pACYC-mvaE-mvaS-ispA-AaFS is constructed by utilizing an enzyme digestion-connection method, and two plasmids pET28a-AaFS-ispA-idi are constructed by utilizing a Gibbson assembly method. The above two plasmids and the third plasmid pTrc-low were transformed into E.coli BL21(DE3) and subjected to shake flask fermentation and 5L fermenter fed-batch fermentation, respectively. A sample containing farnesene is obtained through IPTG induced expression and n-dodecane in-situ extraction, and the sample is quantitatively analyzed through gas chromatography and a farnesene standard substance curve.
Based on the technical scheme, the invention provides a genetically engineered bacterium for synthesizing farnesene, which is a recombinant bacterium for over-expressing acetyl Co-A acyltransferase/HMG-CoA reductase mvaE gene, HMG-CoA synthetase mvaS gene, mevalonate-5-phosphate kinase ERG8, mevalonate kinase ERG12, mevalonate-5-diphosphate decarboxylase ERG19, β -farnesene synthetase AaFS gene, isopentenyl diphosphate isomerase idi gene and farnesyl diphosphate synthetase ispA gene, wherein the copy number of the β -farnesene synthetase AaFS gene, idi gene and ispA gene is2, and the starting strain is escherichia coli.
The β -farnesene synthetase AaFS gene is derived from artemisia apiacea and is obtained after optimization according to codon preference of escherichia coli, the nucleotide sequence of the gene is shown as SEQ ID No. 1, the ispA gene is derived from escherichia coli Top10, the nucleotide sequence of the gene is shown as SEQ ID No. 2, the idi gene is derived from escherichia coli BL21(DE3), and the nucleotide sequence of the gene is shown as SEQ ID No. 3.
Further defined, the Escherichia coli is BL21(DE 3).
The invention also provides a construction method of the gene engineering bacteria for synthesizing farnesene, which comprises the following steps:
1) constructing plasmid pACYC-mvaE-mvaS-ispA-AaFS by optimizing gene sequence of β -farnesene synthetase AaFS according to codon preference of escherichia coli and constructing the plasmid pACYC-mvaE-mvaS-ispA carrier in a enzyme digestion-connection mode to obtain plasmid pACYC-mvaE-mvaS-ispA-AaFS;
2) construction of plasmid pET28 a-AaFS-ispA-idi:
respectively amplifying a pET28a vector sequence, an AaFS gene, an ispA gene and an idi gene sequence, and constructing and obtaining a pET28a-AaFS-ispA-idi plasmid by a Gibsonassambly method; the pET28a vector sequence is shown in SEQ ID No. 4;
3) and (3) plasmid transformation: and (3) transforming the plasmids constructed in the steps 1) and 2) and the pTrc-low plasmid into an escherichia coli host cell together to obtain the genetically engineered bacterium for synthesizing farnesene.
Further limiting, after the β -farnesene synthetase AaFS gene is optimized in step 1), restriction enzyme BglII and XhoI restriction sites are respectively added at two ends of the gene, the gene is synthesized and cloned on a pUC57-simple vector, the obtained plasmid pUC57-AaFS is subjected to double enzyme digestion by the restriction enzyme BglII and XhoI, the AaFS gene restriction product is recovered, pACYC-mvaE-mvaS-ispA is subjected to double enzyme digestion by the restriction enzyme BglII and XhoI, the 8260bp fragment is recovered, and the two recovered fragments are subjected to T4And connecting the DNA ligase to obtain a plasmid pACYC-mvaE-mvaS-ispA-AaFS.
Further limiting, the sequence of an upstream primer for amplifying the pET28a vector sequence in the step 2) is shown as SEQ ID No. 5, and the sequence of a downstream primer is shown as SEQ ID No. 6; the sequence of the upstream primer for AaFS gene amplification is shown as SEQ ID No. 7, and the sequence of the downstream primer is shown as SEQ ID No. 8; the upstream primer sequence for ispA gene amplification is shown as SEQ ID No. 9, and the downstream primer sequence is shown as SEQ ID No. 10; the sequence of the upstream primer for the amplification of the idi gene is shown as SEQ ID No. 11, and the sequence of the downstream primer is shown as SEQ ID No. 12.
The invention also provides application of the genetic engineering bacteria in synthesizing farnesene.
Further limiting, the application is that after the genetically engineered bacteria are cultured by a primary seed culture medium, the obtained seed liquid is inoculated into a shake flask fermentation culture medium for fermentation to obtain farnesene; or after the genetically engineered bacteria are sequentially cultured by a first-stage seed culture medium and a second-stage seed culture medium, inoculating the obtained second-stage seed liquid into a fermentation culture medium of a fermentation tank for fermentation to obtain farnesene.
Further limited, the primary seed culture medium is an LB culture medium, and the components of the primary seed culture medium are as follows: 10g/L NaCl, 10g/L peptone, 5g/L yeast extract, and the balance water.
Further defined, the secondary seed medium comprises: 20g/L glucose, 9.8g/L K2HPO45g/L beef extract, 0.3g/L ferric ammonium citrate, 2.1g/L citric acid monohydrate, 0.06g/L MgSO41mL/L of a trace element solution containing (NH)4)6Mo7O24·4H2O 0.37g/L、ZnSO4·7H2O 0.29g/L、H3BO32.47g/L、CuSO4·5H2O0.25g/L and MnCl2·4H2O1.58 g/L; the fermentation medium is added with betaine with the final concentration of 1g/L on the basis of the secondary seed culture medium, and the final concentration of the trace element solution is 1.5 mL/L.
The gene engineering bacteria for synthesizing farnesene provided by the invention are used in the construction process:
the plasmid pACYC-mvaE-mvaS-ispA is constructed by adopting pACYCDuet-1 as an original empty vector, and is described in Zhang H, Liu Q, Cao Y, Feng X, Zheng Y, Zou H, Liu H, YangJ, Xian M.2014.Microbiological process of sabinene-a new depending-based precorred precursorof advanced biological.Microbiological Cell Factories 13: 20.
The plasmid pTrc-low, vector map is shown in fig. 2 c, the original empty vector adopted during construction is pTrcHIS2b, the plasmid pTrc-low is described in Zhang H, Liu Q, Cao Y, Feng X, Zheng Y, Zou H, Liu H, Yang J, Xian M.2014. Microbiological process of combining gene-a new depending-based plasmid of advanced biological of Microbiological cells 13:20, the plasmid contains a copy number of idi gene.
Advantageous effects
1. The invention increases the heterologous copy numbers of key genes idi, ispA and AaFS in the farnesene synthesis pathway to 2. Compared with BL21(DE3) engineering bacteria introduced with heterologous MVA ways containing one gene respectively, the yield of farnesene synthesized by the engineering bacteria containing three plasmids provided by the invention reaches 2.01g/L in a shake flask level, and the yield is improved by nearly 300 times; the fermentation tank level reaches 12.73g/L, which is the highest yield of farnesene synthesized by the currently known Escherichia coli.
2. The method disclosed by the invention has the characteristics of short growth and fermentation period, low culture cost, simple genetic operation and the like, the yield of the farnesene synthesized by escherichia coli is further improved, the produced farnesene has the advantages of higher yield and purity, no toxicity and harmlessness, and compared with plant extraction and chemical synthesis, the method is a more economic, environment-friendly and sustainable production mode and is more beneficial to promoting the industrial process of synthesizing the farnesene by a biological method.
Drawings
FIG. 1 is a synthesis pathway for farnesene.
In FIG. 2, a is a plasmid map of pACYC-mvaE-mvaS-ispA-AaFS; b is a plasmid map of pET28a-AaFS-ispA-idi, and c is a vector map of pTrc-low.
FIG. 3 shows the yield of farnesene by horizontal shake flask fermentation, wherein a is the shake flask fermentation result of genetically engineered bacteria containing two plasmids, the abscissa is fermentation time (h), and the ordinate (left) is OD600The ordinate (right) of the absorbance of (A) is the farnesene yield (mg/L); b is the shake flask fermentation result containing the three-plasmid genetic engineering bacteria, the abscissa is fermentation time (h), and the ordinate (left) is OD600The absorbance of (D) is plotted on the ordinate (right) as farnesene production (g/L).
FIG. 4 shows the horizontal fermentation yield of farnesene in a fermenter, the abscissa shows the fermentation time (h) and the ordinate shows the farnesene yield (g/L).
Detailed Description
The plasmids pACYCDuet-1, pTrcHIS2b, pET28a, E.coli BL21(DE3), competent cells, primers, reagents and the like used in the examples were commercially available or obtained by conventional means well known to those skilled in the art.
Wherein:
restriction enzyme BglII was purchased from Thermo Scientific, cat #: FD 0083.
Restriction enzyme XhoI was purchased from Thermo Scientific, cat #: FD 0694.
T4Ligase purchaseBought from NEB, cat number: M0202S.
The primers were synthesized from: qingdao Zhixi Biotechnology Limited.
Coli Top10, purchased from Huada Gene.
CmrRepresents chloramphenicol resistance; kanrRepresents kanamycin resistance; amprRepresents ampicillin. The strain provided by the invention is Escherichia coli (Escherichia coli) BL21(DE3), the contained plasmids are pACYC-mvaE-mvaS-ispA-AaFS, pTrc-low and pET28a-AaFS-ispA-idi, and the plasmids are respectively constructed by a method of enzyme digestion-ligation or Gibson assembly (Gibson assembly).
The farnesene synthesis pathway constructed by the invention is shown in figure 1, and consists of plasmids pACYC-mvaE-mvaS-ispA-AaFS, pET28a-AaFS-ispA-idi, pTrc-low and MEP pathway of escherichia coli. Among them, acetyl Co-A acyltransferase/HMG-CoA reductase mvaE gene is one copy, which catalyzes two-step reaction.
Example 1. construction method of genetically engineered bacterium for synthesizing farnesene.
1) Plasmid pACYC-mvaE-mvaS-ispA-AaFS is constructed by optimizing the codon preference of escherichia coli on β -farnesene synthetase AaFS gene sequence from sweet wormwood, respectively adding restriction enzyme BglII and XhoI restriction sites at two ends, synthesizing the sequence from Huada gene, wherein the synthesized sequence is shown as SEQ ID No. 1, cloning AaFS gene with BglII and XhoI restriction sites after synthesis to pUC57-simple vector, and obtaining plasmid by enzyme digestion-connection method according to the instruction of the vector use, wherein the plasmid is marked as pUC57-AaFS, the plasmid pACYC-mvaE-mvaS-ispA-FS (shown as a in the vector map 2) is constructed by adopting enzyme digestion-connection method, firstly, and the restriction enzyme BglII and XhoI are respectively used for carrying out double digestion on plasmid pACYC-mvaE-pUCA-pUCa and ISpA 57-FS, and the enzyme digestion system is as follows:
Figure BDA0001816594430000051
carrying out agarose gel electrophoresis and target band gel cutting recovery on products after enzyme digestion, wherein pACYC-mvaE-mvaS-ispA is subjected to BglII and XhoI double enzyme digestion to recover 8260bp fragments as a vector, pUC57-AaFS is subjected to BglII and XhoI double enzyme digestion to recover 1725bp fragments as inserted fragments, and the recovered products are subjected to ligation reaction:
Figure BDA0001816594430000052
ligation product 10. mu.L of heat shock transformed DH5 α competent cells and plated with LB CmrPlates were incubated overnight at 37 ℃. Observing the colony condition on the plate the next day, selecting single bacteria to fall into a liquid culture medium, culturing at 37 ℃ until the single bacteria are concentrated, carrying out colony PCR identification or extraction plasmid enzyme digestion identification, and sending to sequencing.
2) Construction of plasmid pET28 a-AaFS-ispA-idi:
construction of plasmid pET28a-AaFS-ispA-idi (shown as b in the attached figure 2) by Gibson Assembly method, firstly, pET28a vector and three gene fragments of AaFS, ispA and idi are amplified, and pET28a plasmid, pUC57-AaFS plasmid, pACYC-mvaE-mvaS-ispA plasmid and Escherichia coli BL21(DE3) bacterial liquid are respectively used as templates:
Figure BDA0001816594430000053
the upstream primer sequence for pET28a vector sequence amplification is shown as SEQ ID No. 5, and the downstream primer sequence is shown as SEQ ID No. 6; the sequence of the upstream primer for AaFS gene amplification is shown as SEQ ID No. 7, and the sequence of the downstream primer is shown as SEQ ID No. 8; the upstream primer sequence for ispA gene amplification is shown as SEQ ID No. 9, and the downstream primer sequence is shown as SEQ ID No. 10; the sequence of the upstream primer for the amplification of the idi gene is shown as SEQ ID No. 11, and the sequence of the downstream primer is shown as SEQ ID No. 12.
Subjecting the PCR product to agarose gel electrophoresis and target band gel cutting recovery, determining the concentration of gel recovery product, performing Gibson assembly using NEBuilder kit, calculating the proportion of fragments and the amount of each component according to the instruction, performing ligation reaction at 50 deg.C for 60min, diluting the product with equal volume of sterile water, taking 5 μ L of heat shock-transformed DH5 α competent cells and coating LBKanrPlate, incubated at 37 deg.CAnd (4) at night. Observing the colony condition on the plate the next day, selecting single bacteria to fall into a liquid culture medium, culturing at 37 ℃ until the single bacteria are concentrated, carrying out colony PCR identification or extraction plasmid enzyme digestion identification, and sending to sequencing.
The ispA nucleotide sequence is shown as SEQ ID No. 2; the idi nucleotide sequence is shown as SEQ ID No. 3, and the pET28a vector sequence is shown as SEQ ID No. 4.
3) And (3) plasmid transformation:
e.coli BL21(DE3) competent cells are transformed by thermally shocking plasmids pACYC-mvaE-mvaS-ispA-AaFS, pTrc-low and pET28a-AaFS-ispA-idi (triplasmid) with correct sequencing, corresponding triple-antibody (Cm, Amp and Kan) LB culture medium plates are coated, wherein the final concentration of Cm in LB culture medium is 34mg/L, the final concentration of Amp in LB culture medium is 100mg/L, and the final concentration of Kan in LB culture medium is 50mg/L, and the E.coli is cultured at 37 ℃ until a single colony grows out to obtain the farnesene-synthesizing genetically engineered bacteria.
In the embodiment, recombinant bacteria of genetically engineered bacteria over-expressing acetyl Co-A acyltransferase/HMG-CoA reductase mvaE gene, HMG-CoA synthetase mvaS gene, mevalonate-5-phosphokinase ERG8 gene, mevalonate kinase ERG12 gene, mevalonate-5-diphospho decarboxylase ERG19 gene, β -farnesene synthetase AaFS gene, isopentenyl diphosphate isomerase idi gene and farnesyl diphosphate synthetase ispA gene are obtained, wherein the copy number of the β -farnesene synthetase AaFS gene, idi gene and ispA gene is 2.
Comparative example 1. example 1 was repeated, except that in this comparative example, in step 3), E.coli BL21(DE3) competent cells were transformed by heat shock using plasmids pACYC-mvaE-mvaS-ispA-AaFS and pTrc-low (two plasmids in total) whose sequencing was correct, and LB medium plates were plated with the corresponding diabodies (Cm and Amp) at a final concentration of 34mg/L in LB medium and 100mg/L in LB medium, and cultured at 37 ℃ until single colonies grew out. The ispA, AaFS and idi genes in the genetic engineering bacteria obtained by the comparative example are respectively 1 copy.
Example 2. application of the genetically engineered bacterium constructed in example 1 in the synthesis of farnesene.
In the embodiment, the quantitative detection of farnesene is carried out by using gas chromatography, a chromatographic column is an Agilent DB-5MS (30m multiplied by 0.25mm multiplied by 0.25 mu m) capillary column, and the temperature rise program of the column is that the initial temperature is kept at 60 ℃ for 0.75min, the temperature is raised to 180 ℃ at the speed of 10 ℃/min, then the temperature is lowered to the initial temperature, and β -farnesene standard substance is used for making a standard curve for quantification.
In this embodiment, the primary seed culture medium is an LB culture medium, and comprises the following components: 10g/L NaCl, 10g/L peptone, 5g/L yeast extract, and the balance water.
The secondary seed culture medium comprises the following components: 20g/L glucose, 9.8g/L K2HPO45g/L beef extract, 0.3g/L ferric ammonium citrate, 2.1g/L citric acid monohydrate, 0.06g/L MgSO41mL/L of a trace element solution containing (NH)4)6Mo7O24·4H2O 0.37g/L、ZnSO4·7H2O 0.29g/L、H3BO32.47g/L、CuSO4·5H2O0.25g/L and MnCl2·4H2O1.58g/L, wherein the concentration is the final concentration of each component in the trace element solution; the fermentation medium is added with betaine with the final concentration of 1g/L on the basis of the secondary seed culture medium, and the final concentration of the trace element solution is 1.5 mL/L.
1. Taking a shake flask fermentation method as an example, the application of the genetically engineered bacterium constructed in example 1 in the synthesis of farnesene is described.
Selecting a single colony of the genetically engineered bacteria obtained in the example 1 to 5mL of LB culture medium containing corresponding resistance (Cm/Amp/Kan), carrying out shake culture at 37 ℃ for 8-12 h to obtain a primary seed solution, fermenting the primary seed solution by using a saline bottle with the volume of 600mL, transferring 500 mu L of the primary seed solution to 50mL of fermentation culture medium containing corresponding resistance (Cm, Amp and Kan), and carrying out culture at 37 ℃ until OD is achieved600Adding IPTG (isopropyl thiogalactoside) with a final concentration of 0.1mM and 10mL of n-dodecane into the mixture at about 0.6-0.8, performing shake culture at 30 ℃, sampling for 24h, 48h and 72h respectively, and measuring OD (optical density) by a spectrophotometer600The fermentation product is β -farnesene identified by gas chromatography-mass spectrometry, and the farnesene yield is determined by gas chromatography and three repetitions are set.
Control group: the one obtained in comparative example 1 was picked upSingle colony is subjected to shake flask fermentation to synthesize farnesene, sampling for 24h, 48h and 72h respectively, and measuring OD with spectrophotometer600Farnesene production was determined by gas chromatography in triplicate.
As shown in the attached figure 3, at the shake flask fermentation level, when the engineering bacteria containing two plasmids in the comparative example 1 is fermented for 48 hours, the farnesene yield is only at the milligram level and is close to 6mg/L (shown as a in the attached figure 3), while the engineering bacteria containing three plasmids (the copy numbers of β -farnesene synthetase AaFS gene, idi gene and ispA gene in the engineering bacteria are all 2) constructed by the invention are fermented for 48 hours, the yield is close to 2g/L, the yield is improved by about 300 times, and when the fermentation time is up to 72 hours, the farnesene yield is further improved to 2.01g/L (shown as b in the attached figure 3).
2. The application of the genetically engineered bacterium constructed in example 1 in the synthesis of farnesene is described by taking a fed-batch fermentation method as an example.
First-stage seed liquid: picking the single colony obtained in the step 3) in the embodiment 1 into 5mL of LB culture medium containing corresponding resistance, and carrying out shake culture at 37 ℃ for 8-12 h to obtain a first-level seed solution.
Secondary seed liquid: 1mL of the primary seed solution was transferred to 100mL of LB medium containing the corresponding resistance (Cm/Amp/Kan) and shake-cultured overnight at 37 ℃. Preparing 2L of fermentation medium in the morning of the first day, pouring into a fermentation tank with the volume of 5L, sterilizing at 115 ℃ for 30min, connecting a temperature electrode, a pH electrode, an oxygen dissolving electrode and supply pipes of the tank to a fermentation controller, opening an air valve, adjusting the stirring speed to 300r/min, opening condensed water to reduce the temperature of the medium to 37 ℃, adjusting the pH to about 6.9, and adding 100mL and 3mL of secondary seed liquid, trace elements and corresponding antibiotics (Cm, Amp and Kan). Observing whether the dissolved oxygen and the pH value are normal or not, and if foam exists, adding a defoaming agent dropwise. OD was measured every three hours600OD after about 9 hours600When 11 was reached, the temperature was first reduced to 30 ℃ and then IPTG and 400mL of n-dodecane were added to a final concentration of 0.1mM, after which glucose was supplemented at a rate of 3% and cultured overnight. And gradually adjusting the stirring speed to 600r/min in the morning, adding IPTG every eight hours, frequently checking the dissolved oxygen and pH change, and accelerating the sugar adding rate if the dissolved oxygen is suddenly increased. Every 24 th hourThe yield (aqueous phase, organic phase, tail gas) was measured at one time. As shown in the attached figure 4, the yield of the farnesene reaches 12.73g/L in 48h, which exceeds the highest yield of 8.74g/L of farnesene synthesized horizontally in an escherichia coli fermentation tank reported in the current literature.
SEQUENCE LISTING
<110> institute of bioenergy and Process in Qingdao, China academy of sciences
<120> genetic engineering bacterium for synthesizing farnesene, construction method and application thereof
<130>
<160>12
<170>PatentIn version 3.5
<210>1
<211>1725
<212>DNA
<213> optimized farnesene synthetase AaFS gene sequence
<400>1
atgagcaccc tgccgattag cagtgtgagc tttagtagta gcaccagtcc gctggtggtg 60
gatgataaag tgagcaccaa accggatgtt attcgccata ccatgaattt taatgcaagt 120
atttggggtg accagtttct gacctatgat gaaccggaag atttggttat gaaaaaacag 180
ctggtggaag aactgaaaga agaagtgaaa aaagaactga ttaccattaa gggcagtaat 240
gaaccgatgc agcatgttaa actgattgaa ctgattgatg ccgttcagcg tctgggtatt 300
gcctatcatt ttgaagaaga aattgaggaa gcactgcagc atattcatgt gacctatggc 360
gaacagtggg ttgataaaga aaatctgcag agcattagtc tgtggtttcg tctgctgcgt 420
cagcagggct ttaatgttag cagtggcgtt tttaaagatt ttatggatga aaagggcaag 480
tttaaagaaa gcctgtgcaa tgatgcccag ggtattctgg cactgtatga agccgccttt 540
atgcgtgtgg aagatgaaac cattctggat aatgccctgg agtttactaa agtgcatctg 600
gatattattg caaaagatcc gagttgtgat agcagtctgc gcacccagat tcatcaggcc 660
ctgaaacagc cgctgcgtcg ccgcctggcc cgtattgaag ccctgcatta tatgccgatc 720
tatcagcagg aaaccagcca tgatgaagtt ctgctgaaac tggccaaact ggattttagt 780
gtgctgcaga gtatgcataa aaaagaatta agtcacatct gcaagtggtg gaaagatttg 840
gatctgcaga ataagctgcc gtatgttcgt gatcgcgttg tggaaggtta tttttggatt 900
ctgagtatct attacgagcc gcagcacgct cgtacccgca tgtttctgat gaaaacctgt 960
atgtggctgg ttgttctgga tgataccttt gataattatg gtacatacga agaactggaa 1020
atttttaccc aggccgttga acgttggagt attagctgtc tggatatgct gccggaatat 1080
atgaaactga tctatcagga actggttaat ctgcatgtgg aaatggaaga aagcctggaa 1140
aaagaaggca aaacctatca gattcattat gttaaagaga tggccaaaga actggtgcgc 1200
aattatctgg ttgaagcccg ctggctgaaa gaaggctata tgccgaccct ggaagaatat 1260
atgagcgtta gcatggtgac cggcacctat ggtctgatga ttgcacgcag ttatgtgggt 1320
cgcggcgata ttgttaccga agataccttt aaatgggtta gcagctatcc gccgattatt 1380
aaggccagct gtgttattgt gcgcctgatg gatgatattg tgagtcataa agaagaacag 1440
gaacgtggtc atgttgccag tagcattgaa tgttatagta aagaaagcgg cgcaagtgaa 1500
gaagaagcat gtgaatatat tagccgcaaa gttgaagatg cctggaaagt gattaatcgt 1560
gaaagtctgc gtccgaccgc cgttccgttt ccgctgctga tgccggccat taatctggcc 1620
cgtatgtgtg aagttctgta tagtgtgaat gatggtttta cccatgcaga aggtgacatg 1680
aaaagctata tgaaaagttt ctttgtgcac ccgatggttg tttaa 1725
<210>2
<211>900
<212>DNA
<213> ispA Gene
<400>2
atggactttc cgcagcaact cgaagcctgc gttaagcagg ccaaccaggc gctgagccgt 60
tttatcgccc cactgccctt tcagaacact cccgtggtcg aaaccatgca gtatggcgca 120
ttattaggtg gtaagcgcct gcgacctttc ctggtttatg ccaccggtca tatgtttggc 180
gttagcacaa acacgctgga cgcacccgct gctgccgtag agtgtatcca cgcttactca 240
ttaattcatg atgatttacc ggcgatggat gatgacgatc tgcgccgcgg tttgccgacc 300
tgccatgtga agtttggcga agcaaacgcg attctcgctg gcgacgcttt acaaacgctg 360
gcgttctcga ttctaagcga tgccgatatg ccggaagtgt cggatcgcga cagaatttcg 420
atgatttctg aactggcgag cgccagcggt attgccggaa tgtgcggtgg tcaggcacta 480
gatttagacg cggaaggcaa acacgtacct ctggacgcgc ttgagcgtat tcatcgtcat 540
aaaaccggcg cattgattcg cgccgccgtt cgccttggtg cattaagcgc cggagataaa 600
gggcgtcgtg ctctgccagt actcgacaag tacgcagaga gcatcggcct tgccttccag 660
gttcaagatg acatcctgga tgtggtagga gatactgcaa cgttgggaaa acgccagggt 720
gccgaccagc aacttggtaa aagtacctac cctgcacttc tgggtcttga gcaagcccgg 780
aagaaagccc gggatctgat cgacgatgcc cgtcagtcgc tgaaacaact ggctgaacag 840
tcactcgata cctcggcact ggaagcgcta gcggactaca tcatccagcg taataaataa 900
<210>3
<211>549
<212>DNA
<213> idi Gene
<400>3
atgcaaacgg aacacgtcat tttattgaat gcacagggag ttcccacggg tacgctggaa 60
aagtatgccg cacacacggc agacaccctc ttacatctcg cgttctccag ttggctgttt 120
aatgccaagg ggcaattatt agttacccgc cgcgcactga gcaaaaaagc atggcctggc 180
gtgtggacta actcggtttg tgggcaccca caactgggag aaagcaacga agacgcagtg 240
atccgccgtt gccgttatga gcttggcgtg gaaattacgc ctcctgaatc tatctatcct 300
gactttcgct atcgcgccac cgatccgaat ggcattgtgg aaaatgaagt gtgtccggta 360
tttgccgcac gcaccaacag tgcgttacag atcaacgatg atgaagtgat ggattatcaa 420
tggtgtgatt tagcagatgt attacacggt attgatgcca cgccgtgggc gttcagtccg 480
tggatggtaa tgcaggcagc caatagtgaa gcaagaaaat tgttgtctgc tttcgcgcag 540
cacaattaa 549
<210>4
<211>5279
<212>DNA
<213> pET28a vector sequence
<400>4
ggatccgaat tcgagctccg tcgacaagct tgcggccgca ctcgagcacc accaccacca 60
ccactgagat ccggctgcta acaaagcccg aaaggaagct gagttggctg ctgccaccgc 120
tgagcaataa ctagcataac cccttggggc ctctaaacgg gtcttgaggg gttttttgct 180
gaaaggagga actatatccg gattggcgaa tgggacgcgc cctgtagcgg cgcattaagc 240
gcggcgggtg tggtggttac gcgcagcgtg accgctacac ttgccagcgc cctagcgccc 300
gctcctttcg ctttcttccc ttcctttctc gccacgttcg ccggctttcc ccgtcaagct 360
ctaaatcggg ggctcccttt agggttccga tttagtgctt tacggcacct cgaccccaaa 420
aaacttgatt agggtgatgg ttcacgtagt gggccatcgc cctgatagac ggtttttcgc 480
cctttgacgt tggagtccac gttctttaat agtggactct tgttccaaac tggaacaaca 540
ctcaacccta tctcggtcta ttcttttgat ttataaggga ttttgccgat ttcggcctat 600
tggttaaaaa atgagctgat ttaacaaaaa tttaacgcga attttaacaa aatattaacg 660
tttacaattt caggtggcac ttttcgggga aatgtgcgcg gaacccctat ttgtttattt 720
ttctaaatac attcaaatat gtatccgctc atgaattaat tcttagaaaa actcatcgag 780
catcaaatga aactgcaatt tattcatatc aggattatca ataccatatt tttgaaaaag 840
ccgtttctgt aatgaaggag aaaactcacc gaggcagttc cataggatgg caagatcctg 900
gtatcggtct gcgattccga ctcgtccaac atcaatacaa cctattaatt tcccctcgtc 960
aaaaataagg ttatcaagtg agaaatcacc atgagtgacg actgaatccg gtgagaatgg 1020
caaaagttta tgcatttctt tccagacttg ttcaacaggc cagccattac gctcgtcatc 1080
aaaatcactc gcatcaacca aaccgttatt cattcgtgat tgcgcctgag cgagacgaaa 1140
tacgcgatcg ctgttaaaag gacaattaca aacaggaatc gaatgcaacc ggcgcaggaa 1200
cactgccagc gcatcaacaa tattttcacc tgaatcagga tattcttcta atacctggaa 1260
tgctgttttc ccggggatcg cagtggtgag taaccatgca tcatcaggag tacggataaa 1320
atgcttgatg gtcggaagag gcataaattc cgtcagccag tttagtctga ccatctcatc 1380
tgtaacatca ttggcaacgc tacctttgcc atgtttcaga aacaactctg gcgcatcggg 1440
cttcccatac aatcgataga ttgtcgcacc tgattgcccg acattatcgc gagcccattt 1500
atacccatat aaatcagcat ccatgttgga atttaatcgc ggcctagagc aagacgtttc 1560
ccgttgaata tggctcataa caccccttgt attactgttt atgtaagcag acagttttat 1620
tgttcatgac caaaatccct taacgtgagt tttcgttcca ctgagcgtca gaccccgtag 1680
aaaagatcaa aggatcttct tgagatcctt tttttctgcg cgtaatctgc tgcttgcaaa 1740
caaaaaaacc accgctacca gcggtggttt gtttgccgga tcaagagcta ccaactcttt 1800
ttccgaaggt aactggcttc agcagagcgc agataccaaa tactgtcctt ctagtgtagc 1860
cgtagttagg ccaccacttc aagaactctg tagcaccgcc tacatacctc gctctgctaa 1920
tcctgttacc agtggctgct gccagtggcg ataagtcgtg tcttaccggg ttggactcaa 1980
gacgatagtt accggataag gcgcagcggt cgggctgaac ggggggttcg tgcacacagc 2040
ccagcttgga gcgaacgacc tacaccgaac tgagatacct acagcgtgag ctatgagaaa 2100
gcgccacgct tcccgaaggg agaaaggcgg acaggtatcc ggtaagcggc agggtcggaa 2160
caggagagcg cacgagggag cttccagggg gaaacgcctg gtatctttat agtcctgtcg 2220
ggtttcgcca cctctgactt gagcgtcgat ttttgtgatg ctcgtcaggg gggcggagcc 2280
tatggaaaaa cgccagcaac gcggcctttt tacggttcct ggccttttgc tggccttttg 2340
ctcacatgtt ctttcctgcg ttatcccctg attctgtgga taaccgtatt accgcctttg 2400
agtgagctga taccgctcgc cgcagccgaa cgaccgagcg cagcgagtca gtgagcgagg 2460
aagcggaaga gcgcctgatg cggtattttc tccttacgca tctgtgcggt atttcacacc 2520
gcatatatgg tgcactctca gtacaatctg ctctgatgcc gcatagttaa gccagtatac 2580
actccgctat cgctacgtga ctgggtcatg gctgcgcccc gacacccgcc aacacccgct 2640
gacgcgccct gacgggcttg tctgctcccg gcatccgctt acagacaagc tgtgaccgtc 2700
tccgggagct gcatgtgtca gaggttttca ccgtcatcac cgaaacgcgc gaggcagctg 2760
cggtaaagct catcagcgtg gtcgtgaagc gattcacaga tgtctgcctg ttcatccgcg 2820
tccagctcgt tgagtttctc cagaagcgtt aatgtctggc ttctgataaa gcgggccatg 2880
ttaagggcgg ttttttcctg tttggtcact gatgcctccg tgtaaggggg atttctgttc 2940
atgggggtaa tgataccgat gaaacgagag aggatgctca cgatacgggt tactgatgat 3000
gaacatgccc ggttactgga acgttgtgag ggtaaacaac tggcggtatg gatgcggcgg 3060
gaccagagaa aaatcactca gggtcaatgc cagcgcttcg ttaatacaga tgtaggtgtt 3120
ccacagggta gccagcagca tcctgcgatg cagatccgga acataatggt gcagggcgct 3180
gacttccgcg tttccagact ttacgaaaca cggaaaccga agaccattca tgttgttgct 3240
caggtcgcag acgttttgca gcagcagtcg cttcacgttc gctcgcgtat cggtgattca 3300
ttctgctaac cagtaaggca accccgccag cctagccggg tcctcaacga caggagcacg 3360
atcatgcgca cccgtggggc cgccatgccg gcgataatgg cctgcttctc gccgaaacgt 3420
ttggtggcgg gaccagtgac gaaggcttga gcgagggcgt gcaagattcc gaataccgca 3480
agcgacaggc cgatcatcgt cgcgctccag cgaaagcggt cctcgccgaa aatgacccag 3540
agcgctgccg gcacctgtcc tacgagttgc atgataaaga agacagtcat aagtgcggcg 3600
acgatagtca tgccccgcgc ccaccggaag gagctgactg ggttgaaggc tctcaagggc 3660
atcggtcgag atcccggtgc ctaatgagtg agctaactta cattaattgc gttgcgctca 3720
ctgcccgctt tccagtcggg aaacctgtcg tgccagctgc attaatgaat cggccaacgc 3780
gcggggagag gcggtttgcg tattgggcgc cagggtggtt tttcttttca ccagtgagac 3840
gggcaacagc tgattgccct tcaccgcctg gccctgagag agttgcagca agcggtccac 3900
gctggtttgc cccagcaggc gaaaatcctg tttgatggtg gttaacggcg ggatataaca 3960
tgagctgtct tcggtatcgt cgtatcccac taccgagata tccgcaccaa cgcgcagccc 4020
ggactcggta atggcgcgca ttgcgcccag cgccatctga tcgttggcaa ccagcatcgc 4080
agtgggaacg atgccctcat tcagcatttg catggtttgt tgaaaaccgg acatggcact 4140
ccagtcgcct tcccgttccg ctatcggctg aatttgattg cgagtgagat atttatgcca 4200
gccagccaga cgcagacgcg ccgagacaga acttaatggg cccgctaaca gcgcgatttg 4260
ctggtgaccc aatgcgacca gatgctccac gcccagtcgc gtaccgtctt catgggagaa 4320
aataatactg ttgatgggtg tctggtcaga gacatcaaga aataacgccg gaacattagt 4380
gcaggcagct tccacagcaa tggcatcctg gtcatccagc ggatagttaa tgatcagccc 4440
actgacgcgt tgcgcgagaa gattgtgcac cgccgcttta caggcttcga cgccgcttcg 4500
ttctaccatc gacaccacca cgctggcacc cagttgatcg gcgcgagatt taatcgccgc 4560
gacaatttgc gacggcgcgt gcagggccag actggaggtg gcaacgccaa tcagcaacga 4620
ctgtttgccc gccagttgtt gtgccacgcg gttgggaatg taattcagct ccgccatcgc 4680
cgcttccact ttttcccgcg ttttcgcaga aacgtggctg gcctggttca ccacgcggga 4740
aacggtctga taagagacac cggcatactc tgcgacatcg tataacgtta ctggtttcac 4800
attcaccacc ctgaattgac tctcttccgg gcgctatcat gccataccgc gaaaggtttt 4860
gcgccattcg atggtgtccg ggatctcgac gctctccctt atgcgactcc tgcattagga 4920
agcagcccag tagtaggttg aggccgttga gcaccgccgc cgcaaggaat ggtgcatgca 4980
aggagatggc gcccaacagt cccccggcca cggggcctgc caccataccc acgccgaaac 5040
aagcgctcat gagcccgaag tggcgagccc gatcttcccc atcggtgatg tcggcgatat 5100
aggcgccagc aaccgcacct gtggcgccgg tgatgccggc cacgatgcgt ccggcgtaga 5160
ggatcgagat ctcgatcccg cgaaattaat acgactcact ataggggaat tgtgagcgga 5220
taacaattcc cctctagaaa taattttgtt taactttaag aaggagatat accatgggc 5279
<210>5
<211>38
<212>DNA
<213> upstream primer for amplifying pET28a vector sequence
<400>5
ctttcgcgca gcacaattaa ggatccgaat tcgagctc 38
<210>6
<211>20
<212>DNA
<213> downstream primer for amplification of pET28a vector sequence
<400>6
gcccatggta tatctccttc 20
<210>7
<211>38
<212>DNA
<213> upstream primer for AaFS Gene amplification
<400>7
gaaggagata taccatgggc atgagcaccc tgccgatt 38
<210>8
<211>21
<212>DNA
<213> downstream primer for AaFS Gene amplification
<400>8
ttaaacaacc atcgggtgca c 21
<210>9
<211>53
<212>DNA
<213> upstream primer for ispA Gene amplification
<400>9
tgcacccgat ggttgtttaa aggaggttaa ttggatggac tttccgcagc aac 53
<210>10
<211>27
<212>DNA
<213> downstream primer for ispA Gene amplification
<400>10
ttatttatta cgctggatga tgtagtc 27
<210>11
<211>53
<212>DNA
<213> upstream primer for amplification of idi Gene
<400>11
tcatccagcg taataaataa aggaggttaa ttggatgcaa acggaacacg tca 53
<210>12
<211>20
<212>DNA
<213> downstream primer for idi Gene amplification
<400>12
ttaattgtgc tgcgcgaaag 20

Claims (10)

1. A genetically engineered bacterium for synthesizing farnesene is characterized in that the genetically engineered bacterium is a recombinant bacterium for over-expressing acetyl Co-A acyltransferase/HMG-CoA reductase mvaE gene, HMG-CoA synthetase mvaS gene, mevalonate-5-phosphate kinase ERG8, mevalonate kinase ERG12, mevalonate-5-diphosphate decarboxylase ERG19, β -farnesene synthetase AaFS gene, isopentenyl diphosphate isomerase idi gene and farnesyl diphosphate synthetase ispA gene, the copy number of the β -farnesene synthetase AaFS gene, the idi gene and the ispA gene is2, and the starting strain is escherichia coli.
2. The genetically engineered bacterium for synthesizing farnesene according to claim 1, wherein the β -farnesene synthetase AaFS gene is obtained by optimizing the codon preference of escherichia coli, the optimized nucleotide sequence is shown as SEQ ID No. 1, the ispA gene nucleotide sequence is shown as SEQ ID No. 2, and the idi gene nucleotide sequence is shown as SEQ ID No. 3.
3. The genetically engineered bacterium of claim 1, wherein the Escherichia coli is BL21(DE 3).
4. The method for constructing genetically engineered bacteria for synthesizing farnesene according to any one of claims 1 to 3, which comprises the following steps:
1) constructing plasmid pACYC-mvaE-mvaS-ispA-AaFS by optimizing gene sequence of β -farnesene synthetase AaFS according to codon preference of escherichia coli and constructing the plasmid pACYC-mvaE-mvaS-ispA carrier in a enzyme digestion-connection mode to obtain plasmid pACYC-mvaE-mvaS-ispA-AaFS;
2) construction of plasmid pET28 a-AaFS-ispA-idi:
respectively amplifying a pET28a vector sequence, an AaFS gene, an ispA gene and an idi gene sequence, and constructing and obtaining a pET28a-AaFS-ispA-idi plasmid by a Gibson Assembly method; the pET28a vector sequence is shown in SEQ ID No. 4;
3) and (3) plasmid transformation: and (3) transforming the plasmids constructed in the steps 1) and 2) and the pTrc-low plasmid into an escherichia coli host cell together to obtain the genetically engineered bacterium for synthesizing farnesene.
5. The method for constructing genetically engineered bacteria for synthesizing farnesene according to claim 4, wherein restriction enzyme BglII and XhoI cleavage sites are respectively added to two ends of the gene after the gene of β -farnesene synthetase AaFS is optimized in step 1), the gene is synthesized and cloned to a pUC57-simple vector to obtain a plasmid pUC57-AaFS, the restriction enzyme BglII and XhoI double-cleavage is carried out on the plasmid AaFS, an AaFS gene cleavage product is recovered, a 8260bp fragment is recovered from CYpAC-mvaE-mvaS-ispA, and the two cleavage recovery fragments are subjected to T double-cleavage4And connecting the DNA ligase to obtain a plasmid pACYC-mvaE-mvaS-ispA-AaFS.
6. The method for constructing genetically engineered bacteria for synthesizing farnesene according to claim 4, wherein the upstream primer sequence for amplifying the pET28a vector sequence in the step 2) is shown as SEQ ID No. 5, and the downstream primer sequence is shown as SEQ ID No. 6; the sequence of the upstream primer for AaFS gene amplification is shown as SEQ ID No. 7, and the sequence of the downstream primer is shown as SEQ ID No. 8; the upstream primer sequence for ispA gene amplification is shown as SEQ ID No. 9, and the downstream primer sequence is shown as SEQ ID No. 10; the sequence of the upstream primer for the amplification of the idi gene is shown as SEQ ID No. 11, and the sequence of the downstream primer is shown as SEQ ID No. 12.
7. The use of the genetically engineered bacteria of any one of claims 1 to 3 in the synthesis of farnesene.
8. The application of the genetically engineered bacteria in the synthesis of farnesene according to claim 7, wherein the genetically engineered bacteria are cultured in a primary seed culture medium, and the obtained seed solution is inoculated into a shake flask fermentation culture medium for fermentation to obtain farnesene; or after the genetically engineered bacteria are sequentially cultured by a first-stage seed culture medium and a second-stage seed culture medium, inoculating the obtained second-stage seed liquid into a fermentation culture medium of a fermentation tank for fermentation to obtain farnesene.
9. The use of the synthetic farnesene according to claim 8, wherein the primary seed culture medium is an LB culture medium, and comprises the following components: 10g/L NaCl, 10g/L peptone, 5g/L yeast extract, and the balance water.
10. The use of the synthetic farnesene according to claim 8, wherein the secondary seed medium comprises: 20g/L glucose, 9.8g/L K2HPO45g/L beef extract, 0.3g/L ferric ammonium citrate, 2.1g/L citric acid monohydrate, 0.06g/L MgSO41mL/L of a trace element solution containing (NH)4)6Mo7O24·4H2O0.37g/L、ZnSO4·7H2O 0.29g/L、H3BO32.47g/L、CuSO4·5H2O0.25g/L and MnCl2·4H2O1.58g/L; fermentation cultureThe nutrient medium is added with betaine with the final concentration of 1g/L on the basis of the secondary seed culture medium, and the final concentration of the microelement solution is 1.5 mL/L.
CN201811144959.7A 2018-09-29 2018-09-29 Genetically engineered bacterium for synthesizing farnesene and construction method and application thereof Active CN110964678B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811144959.7A CN110964678B (en) 2018-09-29 2018-09-29 Genetically engineered bacterium for synthesizing farnesene and construction method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811144959.7A CN110964678B (en) 2018-09-29 2018-09-29 Genetically engineered bacterium for synthesizing farnesene and construction method and application thereof

Publications (2)

Publication Number Publication Date
CN110964678A true CN110964678A (en) 2020-04-07
CN110964678B CN110964678B (en) 2022-11-11

Family

ID=70027886

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811144959.7A Active CN110964678B (en) 2018-09-29 2018-09-29 Genetically engineered bacterium for synthesizing farnesene and construction method and application thereof

Country Status (1)

Country Link
CN (1) CN110964678B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111607545A (en) * 2020-04-30 2020-09-01 中国科学院青岛生物能源与过程研究所 Recombinant bacterium for high-yield farnesene as well as construction method and application thereof
CN111607546A (en) * 2020-04-30 2020-09-01 中国科学院青岛生物能源与过程研究所 Genetically engineered bacterium for high-yield farnesene and construction method and application thereof
CN115216464A (en) * 2021-04-19 2022-10-21 武汉合生科技有限公司 Recombinant microorganism for obtaining alpha-farnesene and beta-farnesene and construction method thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007139924A2 (en) * 2006-05-26 2007-12-06 Amyris Biotechnologies, Inc. Apparatus for making bio-organic compounds
US20110160501A1 (en) * 2007-11-13 2011-06-30 Synthetic Genomics, Inc. Dimethyloctane as an Advanced Biofuel
CN103243065A (en) * 2013-05-30 2013-08-14 武汉大学 Bacterial strain for producing farnesene and application of bacterial strain
CN104120141A (en) * 2014-07-14 2014-10-29 青岛农业大学 A method of synthesizing beta-caryophyllene by microbial catalysis and a reconstituted cell capable of synthesizing the beta-caryophyllene
CN107075464A (en) * 2014-09-03 2017-08-18 环球生物能源公司 The recombinant microorganism of alkene is produced from acetyl-COA
CN107418978A (en) * 2017-06-24 2017-12-01 天津大学 A kind of method that farnesene is prepared using biological diesel oil byproduct

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007139924A2 (en) * 2006-05-26 2007-12-06 Amyris Biotechnologies, Inc. Apparatus for making bio-organic compounds
US20110160501A1 (en) * 2007-11-13 2011-06-30 Synthetic Genomics, Inc. Dimethyloctane as an Advanced Biofuel
CN103243065A (en) * 2013-05-30 2013-08-14 武汉大学 Bacterial strain for producing farnesene and application of bacterial strain
CN104120141A (en) * 2014-07-14 2014-10-29 青岛农业大学 A method of synthesizing beta-caryophyllene by microbial catalysis and a reconstituted cell capable of synthesizing the beta-caryophyllene
CN107075464A (en) * 2014-09-03 2017-08-18 环球生物能源公司 The recombinant microorganism of alkene is produced from acetyl-COA
CN107418978A (en) * 2017-06-24 2017-12-01 天津大学 A kind of method that farnesene is prepared using biological diesel oil byproduct

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
刘敏等: "异戊二烯焦磷酸异构酶的表达及其催化功能验证", 《武汉科技大学学报》 *
张建朋等: "鸭梨中α-法尼烯合成酶基因分离与表达分析", 《生物技术通报》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111607545A (en) * 2020-04-30 2020-09-01 中国科学院青岛生物能源与过程研究所 Recombinant bacterium for high-yield farnesene as well as construction method and application thereof
CN111607546A (en) * 2020-04-30 2020-09-01 中国科学院青岛生物能源与过程研究所 Genetically engineered bacterium for high-yield farnesene and construction method and application thereof
CN111607545B (en) * 2020-04-30 2022-08-09 中国科学院青岛生物能源与过程研究所 Recombinant bacterium for high-yield farnesene as well as construction method and application thereof
CN111607546B (en) * 2020-04-30 2022-08-09 中国科学院青岛生物能源与过程研究所 Genetic engineering bacterium for high-yield farnesene and construction method and application thereof
CN115216464A (en) * 2021-04-19 2022-10-21 武汉合生科技有限公司 Recombinant microorganism for obtaining alpha-farnesene and beta-farnesene and construction method thereof

Also Published As

Publication number Publication date
CN110964678B (en) 2022-11-11

Similar Documents

Publication Publication Date Title
CN109486737B (en) Recombinant escherichia coli with high L-tryptophan yield and construction method thereof
CN110964678B (en) Genetically engineered bacterium for synthesizing farnesene and construction method and application thereof
CN107641631A (en) A kind of method that bacillus coli gene is knocked out based on CRISPR/Cas9 systems by chemical conversion mediation
JP6254728B2 (en) Isoprene synthase, polynucleotide encoding the same, and method for producing isoprene monomer
DK2678432T3 (en) RECOMBINANT MICROORGANISMS AND APPLICATIONS THEREOF
CN108148797B (en) Method for producing N-acetylglucosamine by co-utilizing glucose and xylose based on CRISPR
CN101023181A (en) Method for enhancing production of isoprenoid compounds
CN108350412A (en) Method for producing aldehyde
CN108026548A (en) The method that biology prepares methacrylic acid and its derivative
CN104195190B (en) Method for producing 5-aminolevulinic acid by carrying out anaerobic fermentation by utilizing recombinant escherichia coli
CN107231807A (en) Genetic modification phenylpyruvate decarboxylase, preparation method and use
CN114457100A (en) Escherichia coli gene editing system based on CRISPR/Cpf1 and application thereof
CN109576239B (en) Heat-resistant phosphorylase and application thereof
CN111607546B (en) Genetic engineering bacterium for high-yield farnesene and construction method and application thereof
CN109554322B (en) Recombinant Escherichia coli with high L-threonine yield and construction method thereof
US10480003B2 (en) Constructs and systems and methods for engineering a CO2 fixing photorespiratory by-pass pathway
CN112430617A (en) Plasmid with negative selection marker for gene modification of corynebacterium glutamicum
CN111849845B (en) Engineering bacterium for producing 5-aminopentanoic acid by whole cell catalysis and preparation method of 5-aminopentanoic acid
CN101603023A (en) The recombination bacillus coli of one temperature-control coexpression exogenous gene and application thereof
CN107502619B (en) Lactobacillus casei gene knockout vector and application thereof
CN108456687A (en) Recombinant expression plasmid, transformant and its application based on lysine concentration control
CN114672508B (en) Construction method of natamycin high-yield strain, strain and application
CN110734926A (en) endoglucanase expression vector and construction method and application thereof
CN101993885A (en) Novel high-efficiency recombinant plasmid vector and application thereof
CN115505595B (en) Metabolizing engineering modified clostridium soloneicum and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant